Risk Biomarker Assessment for Breast Cancer Progression: Replication Precision of Nuclear Morphometry

por Poulin, N., Frost, A., Carraro, A., Mommers, E., Guillaud, M., van Diest, P.J., Grizzle, W., Beenken, S.
Publicado 2003

Targeting ErbB3-mediated stromal–epithelial interactions in pancreatic ductal adenocarcinoma

por Liles, J S, Arnoletti, J P, Kossenkov, A V, Mikhaylina, A, Frost, A R, Kulesza, P, Heslin, M J, Frolov, A
Publicado 2011

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research...

por Steinbild, S, Mross, K, Frost, A, Morant, R, Gillessen, S, Dittrich, C, Strumberg, D, Hochhaus, A, Hanauske, A-R, Edler, L, Burkholder, I, Scheulen, M
Publicado 2007

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

por Strumberg, D, Scheulen, M E, Schultheis, B, Richly, H, Frost, A, Büchert, M, Christensen, O, Jeffers, M, Heinig, R, Boix, O, Mross, K
Publicado 2012

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours

por Strumberg, D, Schultheis, B, Adamietz, I A, Christensen, O, Buechert, M, Kraetzschmar, J, Rajagopalan, P, Ludwig, M, Frost, A, Steinbild, S, Scheulen, M E, Mross, K
Publicado 2008